9 Meters Biopharma, Inc.
NMTRQ
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.04M
Close$
Share Statistics
| Market cap | $1.04 Million |
|---|---|
| Enterprise Value | $-725,468.00 |
| Dividend Yield | $NaN (NaN%) |
| Earnings per Share | $- |
| Beta | - |
| Outstanding Shares | - |
Return
| Return on Equity | 790.59% |
|---|---|
| Return on Assets | -534.74% |
| Return on Invested Capital | 693.44% |
Valuation & Multiples
| P/E Ratio | - |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | 0.02 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | -7.13 |
| Debt to Equity | -0.82 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 31, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 11, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About 9 Meters Biopharma Inc
10 employees
CEO: Sandeep Laumas Operating as a clinical-stage biopharmaceutical firm, 9 Meters Biopharma, Inc. specialized in creating therapies for individuals in North America afflicted by rare digestive illnesses, various gastrointestinal disorders lacking effective...